Related Experiment Videos
Management of arrhythmias in hypertrophic cardiomyopathy
1Department of Cardiological Sciences, St. George's Hospital Medical School, London, UK.
Insights
Hypertrophic cardiomyopathy management focuses on symptom control and risk identification. Low-dose amiodarone shows promise for managing arrhythmias like atrial fibrillation and preventing sudden cardiac death in adults.
Area of Science:
- Cardiology
- Clinical Electrophysiology
Background:
- Hypertrophic cardiomyopathy (HCM) management aims to control symptoms and identify high-risk individuals.
- Arrhythmias, including atrial fibrillation and nonsustained ventricular tachycardia, are prevalent in adult HCM patients.
Purpose of the Study:
- To review the management strategies for arrhythmias in hypertrophic cardiomyopathy.
- To evaluate the role of amiodarone in controlling atrial fibrillation and preventing sudden cardiac death in HCM.
Main Methods:
- Review of current literature and clinical observations regarding arrhythmia management in HCM.
- Analysis of the prognostic significance of atrial fibrillation and nonsustained ventricular tachycardia.
- Evaluation of amiodarone's efficacy and safety in HCM patients.
Main Results:
- Atrial fibrillation in HCM may not portend an ominous prognosis and is often manageable without rapid symptomatic decline.
- Low-dose amiodarone appears effective for both paroxysmal and chronic atrial fibrillation.
- Nonsustained ventricular tachycardia detected via ambulatory ECG monitoring is a key indicator of sudden death risk in adults, with low-dose amiodarone as a primary treatment.
- Sudden death risk is higher in pediatric populations, but predictive markers are less defined.
Conclusions:
- Symptom control and risk stratification are paramount in HCM management.
- Low-dose amiodarone is a potentially valuable therapeutic option for managing atrial fibrillation and reducing sudden death risk in adult HCM patients.
- Further research is needed to clarify the mechanisms of amiodarone's action and the roles of electrophysiological studies and implantable cardioverter-defibrillators in HCM.
Abstract:
In the management of hypertrophic cardiomyopathy the goals should be the control of symptoms, and the identification and treatment of those at high risk. Arrhythmias, particularly atrial fibrillation and nonsustained ventricular tachycardia, are common in adult patients with hypertrophic cardiomyopathy. Atrial fibrillation has long been thought to herald an ominous prognosis, but this is probably not the case, and in the majority of patients atrial fibrillation can be controlled without accelerated symptomatic deterioration. Uncontrolled observations indicate that low-dose amiodarone may be the most useful drug in both paroxysmal and chronic atrial fibrillation. The detection of nonsustained ventricular tachycardia on ambulatory ECG monitoring remains the single most useful indicator of the risk of sudden death in the adult patient, and the treatment of choice is again low-dose amiodarone. The mechanism of sudden death, and the mode of action of amiodarone in preventing it, are not known for certain in the majority of patients. The risk of sudden death is higher in children and adolescents, but arrhythmias are less common, and no useful predictive marker of increased risk has been found. The roles of invasive electrophysiological studies and the implantable cardioverter-defibrillator are still being evaluated.